These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 996500)

  • 21. [The blood pressure-regulating role of the renin-angiotensin system in essential hypertension before and after emotional stress].
    Hartrodt W; Enderlein J; Bauer E; Brosowski KH; Voigt S; Faulhaber HD
    Cor Vasa; 1987; 29(5):360-8. PubMed ID: 3322670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Concentrations of kininogen and prekallikrein in plasma and activity of plasma renin depending on the type of blood pressure response to captopril in patients with arterial hypertension].
    Zebrowska-Lupina I; Kolber-Postepska B; Markiewicz M; Horubała-Bielak G
    Wiad Lek; 1994 Apr; 47(7-8):241-7. PubMed ID: 7941572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pindolol and propranolol on plasma renin and aldosterone in patients with renal allograft.
    Wehling M; Kuhlmann U; Záruba K; Largiadèr F; Keusch G; Studer A; Vetter W
    Clin Nephrol; 1983 Nov; 20(5):231-4. PubMed ID: 6360452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of diazoxide on blood pressure, PRA and plasma aldosterone in hypertensive patients (author's transl)].
    Mantero F; Perini A; Armanini D; Gion M; Opocher G; Boscaro M
    G Ital Cardiol; 1976; 6(7):1246-53. PubMed ID: 1010235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The calcium channel blocker nitrendipine in single- and multiple-agent antihypertensive regimens: preliminary report of a multicenter study.
    Weber MA; Drayer JI
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1077-84. PubMed ID: 6085371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Age-related changes in the renin-angiotensin-aldosterone system and the sympathetic nervous system in patients with essential hypertension].
    Nami R; Martinelli M; Panza F; Pavese G; Carletti F; Buracchi P; Lucani B; Pazzaglia A; Saia F; Gennari C
    Minerva Cardioangiol; 1993 Sep; 41(9):387-95. PubMed ID: 8259235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of severe essential hypertension with labetalol: effect on active and inactive renin.
    Hauger-Klevene JH
    Pharmatherapeutica; 1981; 3(1):46-54. PubMed ID: 7033992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical experiences with carteolol in patients with essential hypertension].
    Viehmann P
    Arzneimittelforschung; 1983; 33(2a):322-5. PubMed ID: 6340701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure and renin during treatment with pindolol.
    Fyhrquist F; Kurppa K; Huuskonen M; Koistinen A
    Acta Med Scand; 1977; 202(1-2):55-60. PubMed ID: 899884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pindolol: effects on blood pressure and plasma renin activity.
    Glassock RJ; Weitzman RE; Bennett CM; Maxwell M; Hamilton B; Winer N; Kirkendall W; Gonasun L
    Am Heart J; 1982 Aug; 104(2 Pt 2):421-5. PubMed ID: 7048878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the beta-receptor blocking agent visken on blood pressure of hypertensive patients, on plasma renin activity and electrolytes.
    Sonkodi S; Pap A; Varró V
    Ther Hung; 1976; 24(2):60-2. PubMed ID: 982340
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pindolol as an antihypertensive agent].
    Pinggera WF; Fitscha P; Stummvoll HK; Wolf A; Dorda P
    Fortschr Med; 1977 Feb; 95(5):310-14. PubMed ID: 838451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting.
    Chalmers JP; Wing LM; Grygiel JJ; West MJ; Graham JR; Bune AJ
    Eur J Clin Pharmacol; 1982; 22(3):191-6. PubMed ID: 7049706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of pindolol on plasma renin activity in patients with essential hypertension.
    Tényi I; Németh M; Jávor T; Nemes J; Czimer J
    Eur J Clin Invest; 1977 Oct; 7(5):325-9. PubMed ID: 411662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients.
    Lancaster R; Goodwin TJ; Peart WS
    Br J Clin Pharmacol; 1976 Jun; 3(3):453-60. PubMed ID: 973972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrinsic sympathomimetic activity counteracts beta-blocker inhibition of renin activation.
    Ruddy MC; Bialy GB; Kostis JB
    Angiology; 1989 Jan; 40(1):45-50. PubMed ID: 2562912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine.
    Winer N; Carter CH; Eddy H
    Am Heart J; 1982 Aug; 104(2 Pt 2):425-31. PubMed ID: 7048879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Adv Clin Pharmacol; 1976; 11():1114-8. PubMed ID: 802071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of 'responders' to long-term pindolol therapy from phasic changes in cardiovascular function during acute intravenous administration in essential hypertension.
    Logan AG; Milne BJ; Colman JM
    Clin Invest Med; 1978; 1(3-4):147-52. PubMed ID: 42504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.